|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:atccode
|
L04 AA18
|
|
gptkbp:chemical_formula
|
C16 H20 N6 O5 P
|
|
gptkbp:clinical_trial
|
Phase 3
|
|
gptkbp:clinical_use
|
chronic inflammatory conditions
|
|
gptkbp:contraindication
|
active infections
severe liver impairment
|
|
gptkbp:dosage_form
|
5 mg tablet
10 mg tablet
11 mg
11 mg tablet
|
|
gptkbp:drug_interactions
|
immunosuppressants
live vaccines
CYP2 C19 inhibitors
CYP3 A4 inhibitors
|
|
gptkbp:duration
|
long-term
|
|
gptkbp:effective_date
|
gptkb:2012
FDA approved
|
|
gptkbp:formulation
|
extended-release tablet
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Xeljanz XR
|
|
gptkbp:ingredients
|
tofacitinib
|
|
gptkbp:is_monitored_by
|
liver function tests
complete blood count
|
|
gptkbp:manufacturer
|
gptkb:Pfizer
|
|
gptkbp:marketed_as
|
gptkb:Xeljanz_XR
|
|
gptkbp:mechanism_of_action
|
Janus kinase inhibitor
|
|
gptkbp:packaging
|
blister pack
|
|
gptkbp:patient_education
|
avoid live vaccines
report signs of infection
adherence to prescribed regimen
monitor for liver issues
|
|
gptkbp:patient_population
|
adults
|
|
gptkbp:provides_guidance_on
|
recommended for moderate to severe cases
|
|
gptkbp:requires
|
gptkb:true
|
|
gptkbp:route_of_administration
|
oral
|
|
gptkbp:safety_measures
|
thromboembolic events
malignancy risk
gastrointestinal perforations
|
|
gptkbp:side_effect
|
headache
nausea
diarrhea
increased risk of infections
elevated liver enzymes
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:trade
|
gptkb:Xeljanz
|
|
gptkbp:type_of_care
|
important for efficacy
|
|
gptkbp:used_for
|
gptkb:ulcerative_colitis
gptkb:rheumatoid_arthritis
gptkb:psoriatic_arthritis
|
|
gptkbp:bfsParent
|
gptkb:Tofacitinib
|
|
gptkbp:bfsLayer
|
6
|